SCHEMBL2092292

SCHEMBL2092292

CN(C(=O)O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPMT P51580 1/20 0.44
ATF1 P18846 1/20 0.43
NFKB1 P19838 1/20 0.43
NOTUM Q6P988 1/20 0.39
FSCN1 Q16658 1/20 0.37
RXRA P19793 2/20 0.37
RXRB P28702 2/20 0.37
RXRG P48443 1/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 2/20 0.36
ACLY P53396 1/20 0.36
POLB P06746 1/20 0.36
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
TACR1 P25103 1/20 0.36
TMEM97 Q5BJF2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092289 0.82 ATF1 (0.43) TPMTATF1NFKB1NOTUMFSCN1
SCHEMBL12436239 0.80 ATF1 (0.42) TPMTATF1NFKB1NOTUMFSCN1
SCHEMBL2097580 0.80 POLB (0.39) FSCN1ALDH1A1TSHRPOLBCASP1
SCHEMBL31715773 0.79 HTR3E (0.61) NFKB1ALDH1A1GAATSHRPOLB
SCHEMBL2096198 0.79 HTR3E (0.61) NFKB1ALDH1A1GAATSHRPOLB
SCHEMBL7108360 0.78 S1PR2 (0.41) ATF1NFKB1RXRARXRBRXRG
SCHEMBL692996 0.77 ALDH1A1 (0.48) ALDH1A1TSHRPOLBSMN1; SMN2
SCHEMBL2091610 0.77 ATF1 (0.40) TPMTATF1NFKB1RXRARXRB
SCHEMBL11394132 0.77 ATF1 (0.40) TPMTATF1NFKB1FSCN1RXRA
SCHEMBL8563797 0.77 KDM4E (0.53) ATF1NFKB1ALDH1A1TSHRACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 TPMT 2767/4885ATF1 2139/4885NFKB1 1248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.